CIK 0001590750 · Large accelerated filer
Viridian Therapeutics, Inc.\DE
Sign in to watch- Ticker
- VRDN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 471187261
- Phone
- 617.272.4600
- Business address
- 221 CRESCENT STREET, SUITE 103A, WALTHAM, MA, 02453
- Former names
- MIRAGEN THERAPEUTICS, INC., SIGNAL GENETICS, INC., SIGNAL GENETICS LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $348,194
- in 1 filing
Net −$348,194. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-01-17 | Katz Barrett Chief Medical Officer | Sale | −24,853 | $37.21 | $925K | 0 |
| 2023-01-17 | Katz Barrett Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −24,853 | 267,000 | ||
| 2023-01-13 | Katz Barrett Chief Medical Officer | Option exercise | +4,147 | $23.03 | $96K | 4,147 |
| 2023-01-13 | Katz Barrett Chief Medical Officer | Sale | −4,147 | $37.01 | $153K | 0 |
| 2023-01-13 | Katz Barrett Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −4,147 | 291,853 | ||
| 2023-01-10 | Katz Barrett Chief Medical Officer | Option exercise | +47,377 | $23.03 | $1.1M | 47,377 |
| 2023-01-10 | Katz Barrett Chief Medical Officer | Sale | −47,377 | $35.30 | $1.7M | 0 |
| 2023-01-10 | Katz Barrett Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −47,377 | 296,000 | ||
| 2023-01-09 | Katz Barrett Chief Medical Officer | Option exercise | +12,623 | $23.03 | $291K | 12,623 |
| 2023-01-09 | Katz Barrett Chief Medical Officer | Sale | −12,623 | $33.04 | $417K | 0 |
| 2023-01-09 | Katz Barrett Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −12,623 | 343,377 | ||
| 2022-12-21 | Meisner Lara General Counsel and Secretary | Option exercise | +16,326 | $23.03 | $376K | 16,326 |
| 2022-12-21 | Meisner Lara General Counsel and Secretary | Sale | −16,326 | $29.19 | $477K | 0 |
| 2022-12-21 | Meisner Lara General Counsel and Secretary | Option exercise · Stock Option (Right to Buy) | −16,326 | 44,721 | ||
| 2022-12-20 | Meisner Lara General Counsel and Secretary | Option exercise | +600 | $23.03 | $14K | 600 |
| 2022-12-20 | Meisner Lara General Counsel and Secretary | Sale | −600 | $28.07 | $17K | 0 |
| 2022-12-20 | Meisner Lara General Counsel and Secretary | Option exercise · Stock Option (Right to Buy) | −600 | 61,047 | ||
| 2022-12-16 | Meisner Lara General Counsel and Secretary | Option exercise | +1,297 | $23.03 | $30K | 1,297 |
| 2022-12-16 | Meisner Lara General Counsel and Secretary | Sale | −1,297 | $28.44 | $37K | 0 |
| 2022-12-16 | Meisner Lara General Counsel and Secretary | Option exercise · Stock Option (Right to Buy) | −1,297 | 61,647 |
Page 7 of 10 · 182 trades